Page last updated: 2024-09-04

gl 331 and Neoplasms

gl 331 has been researched along with Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chao, Y; Chen, LL; Chen, LT; Chen, MH; Huang, TS; Lee, CC; Shu, CH; Whang-Peng, J; Yuan, CC	1

Other Studies

1 other study(ies) available for gl 331 and Neoplasms

Article	Year
A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharmaceutical research, 1999, Volume: 16, Issue:7 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Death; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Etoposide; Humans; Neoplasms; Podophyllotoxin; Tumor Cells, Cultured	1999

Article

Year

A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells.

Pharmaceutical research, 1999, Volume: 16, Issue:7

Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Death; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Etoposide; Humans; Neoplasms; Podophyllotoxin; Tumor Cells, Cultured

1999